RBC Capital Maintains Outperform Rating on Axsome Therapeutics with PT Raised to $198

martes, 4 de noviembre de 2025, 11:31 am ET1 min de lectura
AXSM--

RBC Capital Maintains Outperform Rating on Axsome Therapeutics with PT Raised to $198

RBC Capital Maintains Outperform Rating on Axsome Therapeutics with PT Raised to $198

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios